Shanghai Pulmonary Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Employees
- -
- Market Cap
- -
Clinical Trials
7
Active:0
Completed:1
Trial Phases
3 Phases
Phase 1:4
Phase 2:1
Not Applicable:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (57.1%)Not Applicable
2 (28.6%)Phase 2
1 (14.3%)No trials found
News
Anti-PD1 Precision Therapy Shows Promise in Unresectable Stage III NSCLC Trial
A phase II umbrella trial demonstrated that anti-PD1 based precision induction therapy achieved a 61.7% major pathological response rate in patients with unresectable stage III non-small cell lung cancer.